AIMD Financials: Ainos Inc AI Analysis

Home

Stock

AIMD

Financials

AIMD Financial

Ainos Inc

$1.46

-8.75%

$-0.14

At close: Mar 24, 16:00:00 GMT-4

$1.45

-0.68%

$-0.01

Post-market: Mar 24, 20:00:00 GMT-4

Overview Forecast Earnings Dividends Financials

Income

Balance sheet

Cash flow

Annual

Quarterly

AIMD Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenue	0	0	0	3	0	0
Revenue Growth (YoY)	--	--	-100%	--	--	--
Cost of Revenue	0	0	0	2	0	0
Gross Profit	0	0	0	1	0	0
Selling, General & Admin	6	5	5	8	2	1
Research & Development	7	8	7	6	1	0
Operating Expenses	14	13	12	15	4	1
Other Non Operating Income (Expenses)	0	0	0	0	0	--
Pretax Income	-14	-14	-13	-14	-3	-1
Income Tax Expense	0	0	0	--	--	--
Net Income	-14	-14	-13	-14	-3	-1
Net Income Growth	-13%	8%	-7%	367%	200%	0%
Shares Outstanding (Diluted)	4.55	1.9	0.81	0.54	0.3	0.1
Shares Change (YoY)	102%	132%	50%	81%	178%	2%
EPS (Diluted)	-3.28	-7.81	-16.8	-25.68	-12.87	-13.34
EPS Growth	-54%	-53%	-35%	100%	-4%	-10%
Free Cash Flow	-4	-5	-4	-3	-1	0
Free Cash Flow Per Share	--	--	--	--	--	--
Gross Margin	0%	0%	0%	33.33%	0%	0%
Operating Margin	0%	0%	0%	-433.33%	0%	0%
Profit Margin	0%	0%	0%	-466.66%	0%	0%
Free Cash Flow Margin	0%	0%	0%	-100%	0%	0%
EBITDA	-10	-9	-9	-9	-1	-1
EBITDA Margin	0%	0%	0%	-300%	0%	0%
D&A For EBITDA	4	4	4	4	2	0
EBIT	-14	-13	-13	-13	-3	-1
EBIT Margin	0%	0%	0%	-433.33%	0%	0%
Effective Tax Rate	0%	0%	0%	--	--	--

Follow-Up Questions

What are Ainos Inc's key financial statements?



According to the latest financial statement (Form-10K), Ainos Inc has a total asset of $28, Net loss of $-14

What are the key financial ratios for AIMD?



Ainos Inc's Current ratio is 2.15, has a Net margin is 0, sales per share of $0.

How is Ainos Inc's revenue broken down by segment or geography?



Ainos Inc largest revenue segment is Point-of-care Testing, Low-dose Interferon Alpha Therapeutics and Synthetic RNA-driven preventative Medicine, at a revenue of 20,729 in the most earnings release.For geography, United States is the primary market for Ainos Inc, at a revenue of 20,729.

Is Ainos Inc profitable?



no, according to the latest financial statements, Ainos Inc has a net loss of $-14

Does Ainos Inc have any liabilities?



yes, Ainos Inc has liability of 13

How many outstanding shares for Ainos Inc?



Ainos Inc has a total outstanding shares of 3.08

Key Stats

Prev.Close

$1.6

Open

$1.57

Day's Range

$1.45 - $1.62

52 week range

$1.26 - $4.5

Volume

45.2K

Avg.Volume

670.0K

Dividend yield

EPS (TTM)

-4.29

Market Cap

$10.1M

What is AIMD?

Ainos, Inc. is a diversified medtech company, which engages in the development of medical technologies for point-of-care testing and safe and novel medical treatment for a broad range of disease indications. The company is headquartered in Houston, Texas and currently employs 44 full-time employees. Its AI Nose platform and smell language model (SML) digitize scent into Smell ID, a machine-readable data, powering applications across robotics, smart factories, and healthcare. The company is also developing VELDONA, an oral low-dose interferon therapy targeting rare diseases, autoimmune diseases, infectious diseases, and animal health. Its pipeline includes drug candidates for treating oral warts for human immunodeficiency virus seropositive patients, Sjogren’s syndrome, and feline chronic gingivostomatitis, a cat oral infection. Its product pipeline includes VELDONA Pet, VELDONA human drugs, AI Nose - NISD co-development, AI Nose industrial and robotics application, VOC POCT, VOC POCT Ainos Pen, VOC POCT CHS430, and Synthetic RNA (SRNA). VOC POCT-Ainos Pen is a device intended to be a cloud-connected, multipurpose, portable breath analyzer that is intended to monitor health conditions.



Features

AI Copilot for Stock & Crypto

Resources